Adrenal Adenoma Treatment & Management
- Author: George T Griffing, MD; Chief Editor: George T Griffing, MD more...
Complications
Complications
Patients are prone to adrenal insufficiency once the cortisol-secreting tumor is removed. This postoperative adrenal insufficiency is caused by corticotropin suppression and adrenal cortical atrophy of the contralateral adrenal gland, described in the image below.
Pituitary-adrenal axis and cortisol-secreting adrenal mass. Consultations
An endocrinologist should be consulted to review the results of endocrine testing.
Approach Considerations
The 2 main concerns with regard to an adrenal incidentaloma (AI) are (1) whether it is hormonally active (functional) and (2) whether it is malignant. Correlation with the clinical presentation and, if necessary, serum chemical and urinalysis results should be used to determine whether an adrenal cortical adenoma is functional. Benign adrenal cortical adenomas are commonly smaller than 6 cm in diameter on initial presentation, but they may be larger.
No specific medical therapy is required except treating the underlying disease.
Nonsurgical treatment
Conditions that do not warrant surgery include bilateral adrenal diseases such as corticotropin-dependent Cushing disease or bilateral hyperaldosteronism. Nonfunctional (hormonally silent) adrenal cortical adenomas are not premalignant, and surgical excision is not indicated.
The AACE/AAES 2009 guidelines add that patients with bilateral idiopathic hyperaldosteronism (IHA) who cannot or choose not to receive surgical treatment should be managed with selective and nonselective mineralocorticoid receptor blockers.[10]
Surgical treatment
The treatment for a hormonally active adrenal tumor is surgery. The treatment for a malignancy depends on the cell type, spread, and location of the primary tumor.[2]
No randomized trials have compared laparotomy versus laparoscopic adrenalectomy; however, abdominal laparotomy is preferred for bilateral disease and pheochromocytoma. Fiberoptic laparoscopy is used for visualization, biopsy, and removal. A transthoracic approach is faster than fiberoptic laparoscopy but has a longer postoperative recovery period.
Other experimental approaches, including a laparoscopic robot and augmented-reality visualization of the surgical field, have been described.
Treatment of metastatic disease
Metastatic disease is managed according to the type of primary cancer. Adrenal disease should be removed if the diameter is greater than 6 cm. Otherwise, follow up with repeat computed tomography (CT) scans at periodic intervals.
Long-Term Monitoring
For patients who do not have an adrenalectomy, follow-up is designed to detect interval changes in tumor size or the development of hormonal overproduction. Most adrenal lesions remain unchanged or decrease in size, whereas 5-25% enlarge. Repeat CT scanning at 6-12 months is recommended, and for lesions that do not increase in size, further testing is generally not warranted.
Annual biochemical evaluation of most patients with adrenal incidentalomas for as long as 5 years may be reasonable, especially if the tumor is larger than 3 cm in size.[26] Patients with adrenal masses smaller than 4 inches who have a noncontrast attenuation value of more than 10 Hounsfield units should have repeat CT scanning in 3-6 months and again annually for 2 years. Any tumors with indeterminate features on radiology that grow to at least 0.8 cm over 3-12 months may be considered for surgical resection.
Overnight 1-mg dexamethasone suppression testing, a renin-to-aldosterone ratio, and urinary catecholamine and metabolite measurements can be performed yearly or more frequently if clinically indicated. After several years, this testing can probably be discontinued.
Hypercortisolism (especially subclinical) is the most likely hormonal disorder to develop in the follow-up period and is subclinical in most cases.
The AACE/AAES 2009 guidelines state that a patient who has undergone a resection due to a pheochromocytoma should receive long-term follow-up because the recurrence rate is 10-15%.[10]
A study by Leboulleux et al found that 18-fluorodeoxyglucose (FDG) uptake occurred in 14-29% of patients within 24 months after adrenalectomy in patients with adrenocortical carcinoma.[27] The uptake is considered transient and is not suspicious for malignancy.
Primary hyperaldosteronism or catecholamine excess is rarely observed during follow up.
Adrenal insufficiency may occur with bilateral adrenal disease such as lymphoma or hemorrhage.
Hypocortisolism may also occur as a result of corticotropin deficiency from a cortisol-secreting adenoma that is causing contralateral adrenal atrophy. The postoperative course for these patients is prolonged physiologic cortisol replacement.
Terzolo M, Bovio S, Pia A, Reimondo G, Angeli A. Management of adrenal incidentaloma. Best Pract Res Clin Endocrinol Metab. Apr 2009;23(2):233-43. [Medline].
Yener S, Ertilav S, Secil M, Demir T, Akinci B, Kebapcilar L, et al. Prospective evaluation of tumor size and hormonal status in adrenal incidentalomas. J Endocrinol Invest. Jan 2010;33(1):32-6. [Medline].
Kokko JP, Brown TC, Berman MM. Adrenal adenoma and hypertension. Lancet. Mar 4 1967;1(7488):468-70. [Medline].
Glazer HS, Weyman PJ, Sagel SS, Levitt RG, McClennan BL. Nonfunctioning adrenal masses: incidental discovery on computed tomography. AJR Am J Roentgenol. Jul 1982;139(1):81-5. [Medline].
Abecassis M, McLoughlin MJ, Langer B, Kudlow JE. Serendipitous adrenal masses: prevalence, significance, and management. Am J Surg. Jun 1985;149(6):783-8. [Medline].
Belldegrun A, Hussain S, Seltzer SE, Loughlin KR, Gittes RF, Richie JP. Incidentally discovered mass of the adrenal gland. Surg Gynecol Obstet. Sep 1986;163(3):203-8. [Medline].
Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery. Dec 1991;110(6):1014-21. [Medline].
Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. J Endocrinol Invest. Apr 2006;29(4):298-302. [Medline].
Sutton MG, Sheps SG, Lie JT. Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series. Mayo Clin Proc. Jun 1981;56(6):354-60. [Medline].
[Guideline] Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, et al. The American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocr Pract. Jul-Aug 2009;15 Suppl 1:1-20. [Medline]. [Full Text].
Schmitz KJ, Helwig J, Bertram S, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol. Jun 2011;64(6):529-35. [Medline]. [Full Text].
Bin X, Qing Y, Linhui W, Li G, Yinghao S. Adrenal incidentalomas: Experience from a retrospective study in a Chinese population. Urol Oncol. May 29 2009;[Medline].
Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. Jul 1998;171(1):201-4. [Medline].
Ho LM, Paulson EK, Brady MJ, Wong TZ, Schindera ST. Lipid-poor adenomas on unenhanced CT: does histogram analysis increase sensitivity compared with a mean attenuation threshold?. AJR Am J Roentgenol. Jul 2008;191(1):234-8. [Medline].
Halefoglu AM, Bas N, Yasar A, Basak M. Differentiation of adrenal adenomas from nonadenomas using CT histogram analysis method: a prospective study. Eur J Radiol. Mar 2010;73(3):643-51. [Medline].
Krestin GP, Steinbrich W, Friedmann G. Adrenal masses: evaluation with fast gradient-echo MR imaging and Gd-DTPA-enhanced dynamic studies. Radiology. Jun 1989;171(3):675-80. [Medline].
Khati NJ, Javitt MC, Schwartz AM. Adrenal adenoma and hematoma mimicking a collision tumor at MR imaging. Radiographics. Jan-Feb 1999;19(1):235-9. [Medline].
Yoh T, Hosono M, Komeya Y, Im SW, Ashikaga R, Shimono T, et al. Quantitative evaluation of norcholesterol scintigraphy, CT attenuation value, and chemical-shift MR imaging for characterizing adrenal adenomas. Ann Nucl Med. Jul 2008;22(6):513-9. [Medline].
Korobkin M. CT characterization of adrenal masses: the time has come. Radiology. Dec 2000;217(3):629-32. [Medline].
Liang HL, Pan HB, Lee YH, Huang JS, Wu TD, Chang CT, et al. Small functional adrenal cortical adenoma: treatment with CT-guided percutaneous acetic acid injection--report of three cases. Radiology. Nov 1999;213(2):612-5. [Medline].
Mayo-Smith WW, Boland GW, Noto RB, Lee MJ. State-of-the-art adrenal imaging. Radiographics. Jul-Aug 2001;21(4):995-1012. [Medline].
Otal P, Escourrou G, Mazerolles C, Janne d'Othee B, Mezghani S, Musso S, et al. Imaging features of uncommon adrenal masses with histopathologic correlation. Radiographics. May-Jun 1999;19(3):569-81. [Medline].
Boland GW, Blake MA, Hahn PF, Mayo-Smith WW. Incidental adrenal lesions: principles, techniques, and algorithms for imaging characterization. Radiology. Dec 2008;249(3):756-75. [Medline].
Muth A, Hammarstedt L, Hellstrom M, et al. Cohort study of patients with adrenal lesions discovered incidentally. Br J Surg. Oct 2011;98(10):1383-1391. [Medline].
Mazzaglia PJ, Monchik JM. Limited value of adrenal biopsy in the evaluation of adrenal neoplasm: a decade of experience. Arch Surg. May 2009;144(5):465-70. [Medline].
Zeiger MA, Siegelman SS, Hamrahian AH. Medical and surgical evaluation and treatment of adrenal incidentalomas. J Clin Endocrinol Metab. Jul 2011;96(7):2004-15. [Medline].
Leboulleux S, Deandreis D, Escourrou C, et al. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy. Eur J Endocrinol. Jan 2011;164(1):89-94. [Medline].
| Author | Method | Sample Size | Prevalence, % |
| Russl (1941) | Autopsy (>1 cm) | 131/9000 | 1.5 |
| Kokko (1967)[3] | Autopsy (>5 mm) | 21/1495 | 1.5 |
| Hedeland (1967) | Autopsy (>2 mm) | 64/739 | 8.7 |
| Glazer (1982)[4] | CT scan | 16/2200 | 0.7 |
| Abecassis (1985)[5] | CT scan | 19/1459 | 1.3 |
| Belldegrun (1986)[6] | CT scan | 88/12000 | 0.7 |
| Herrera (1991)[7] | CT scan | 259/61054 | 0.4 |
| Diagnosis | Features | Biochemical Tests |
| Pheochromocytoma | High blood pressure, catechol symptoms | Urine-free and plasma-free metanephrines |
| Primary aldosteronism | High blood pressure, low K+, low PRA* | Plasma aldosterone-to-renin ratio |
| Adrenocortical carcinoma | Virilization or feminization | Urine 17-ketosteroids |
| Cushing or "silent" Cushing syndrome | Cushing symptoms or normal examination results | Overnight 1-mg dexamethasone test |
| *Plasma renin activity | ||
Print
